孟鲁司特钠联合丙酸倍氯米松气雾剂治疗咳嗽变异性哮喘患儿的效果

Effects of Montelukast sodium combined with Beclomethasone propionate aerosol in treatment of children with cough variant asthma

目的:观察孟鲁司特钠联合丙酸倍氯米松气雾剂治疗咳嗽变异性哮喘(CVA)患儿的效果。方法:选取2018年5月至2021年5月该院收治的76例CVA患儿进行前瞻性研究,按随机数字表法将其分为对照组(n=38)与观察组(n=38)。对照组采用丙酸倍氯米松吸入气雾剂治疗,观察组在对照组基础上联合孟鲁司特钠治疗,比较两组治疗效果、治疗前后肺功能指标[第1秒用力呼气容积(FEV_(1))、用力呼气量(FVC)、FEV_(1)/FVC、呼气流量峰值(PEF)]水平、免疫功能指标[免疫球蛋白E(IgE)、T细胞亚群(CD8^(+)、CD4^(+)、CD3^(+))]水平、炎性因子[白细胞介素-4(IL-4)、C反应蛋白(CRP)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)]水平和不良反应发生率。结果:观察组治疗总有效率为97.37%(37/38),高于对照组的78.95%(30/38),差异有统计学意义(P<0.05);治疗后,观察组FEV_(1)、FVC、FEV_(1)/FVC、PEF水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组CD4^(+)、CD3^(+)水平高于对照组,IgE、CD8^(+)水平低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组IL-4、CRP、IL-10、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合丙酸倍氯米松气雾剂治疗CVA患儿可提高治疗总有效率和肺功能指标水平,改善免疫功能指标水平,以及降低炎性因子水平,其效果优于单纯丙酸倍氯米松吸入气雾剂治疗。

Objective:To observe effects of Montelukast sodium combined with Beclomethasone propionate aerosol in treatment of children with cough variant asthma(CVA).Methods:76 children with CVA admitted to this hospital from May 2018 to May 2021 were selected for the prospective study,and they were divided into control group(n=38)and observation group(n=38)according to random number table method.The control group was given Beclomethasone propionate aerosol treatment,while the observation group was given Montelukast sodium treatment on the basis of that of the control group.The treatment effects,the pulmonary function index levels[forced expiratory volume in 1 second(FEV_(1)),forced expiratory volume(FVC),FEV_(1)/FVC,peak expiratory flow(PEF)],the immune function index levels[immune globulin E(IgE),T cell subsets(CD8^(+),CD4^(+),CD3^(+))],the inflammatory factor levels[interleukin-4(IL-4),C-reactive protein(CRP),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 97.37%(37/38),which was higher than the control group of 78.95%(30/38),and the difference was statistically significant(P<0.05).After the treatment,the levels of FEV_(1),FVC,FEV_(1)/FVC,and PEF in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4^(+) and CD3^(+) in the observation group were higher than those in the control group;the levels of IgE and CD8^(+) were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-4,CRP,IL-10 and TNF-αin the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Beclomethasone propionate aerosol in the treatment of the children with CVA can improve the total effective rate of treatment and the levels of pulmonary function indexes,improve the levels of immune function indexes and reduce the levels of inflammatory factors.Moreover,it is superior to single Beclomethasone propionate aerosol treatment.